INBS (INBS) CEO receives time- and performance-based restricted stock grants

Rhea-AI Filing Summary

Simeonidis Harry reported acquisition or exercise transactions in this Form 4 filing.

Intelligent Bio Solutions Inc. granted Chief Executive Officer Harry Simeonidis new equity awards in the form of restricted common stock. On March 18, 2026, he received 9,150 restricted shares that vest over 48 months, and 21,350 additional restricted shares subject to both performance-based and time-based vesting conditions. These awards were issued at no cash cost under the company’s 2019 Long Term Incentive Plan and are subject to forfeiture until the vesting requirements are met. All share amounts reflect prior reverse stock splits, including a 1-for-10 split effective December 15, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simeonidis Harry

(Last) (First) (Middle)

C/O INTELLIGENT BIO SOLUTIONS INC.,

135 WEST 41ST STREET, 5TH FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INTELLIGENT BIO SOLUTIONS INC. [ INBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/18/2026		A		9,150(2)	A	$0	13,190(1)	D
Common Stock	03/18/2026		A		21,350(3)	A	$0	34,540(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis.

2. On March 18, 2026, the Issuer granted the reporting person 9,150 restricted shares of Common Stock under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan ("2019 Plan"). The awarded shares are subject to time-based vesting after 48 months and are subject to forfeiture until vested.

3. On March 18, 2026, the Issuer granted the reporting person 21,350 restricted shares of Common Stock under the 2019 Plan. The awarded shares are subject to joint performance-based and time-based vesting requirements and are subject to forfeiture until vested.

	/s/ Harry Simeonidis	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did INBS CEO Harry Simeonidis report in this Form 4?

He reported receiving equity compensation in the form of restricted common stock. On March 18, 2026, he was granted 9,150 time-vested shares and 21,350 performance- and time-vested shares under Intelligent Bio Solutions’ 2019 Long Term Incentive Plan.

Are the INBS CEO’s new shares from open-market purchases or grants?

They are grants, not open-market purchases. Both transactions are coded as awards of common stock at a price of $0.0000 per share, issued under the 2019 Long Term Incentive Plan as part of his compensation package.

What are the vesting terms of the 9,150 INBS restricted shares?

The 9,150 restricted shares vest based solely on time. They are subject to time-based vesting over 48 months from March 18, 2026, and may be forfeited if the vesting conditions are not satisfied during that period.

What are the vesting conditions for the 21,350 INBS restricted shares?

The 21,350 restricted shares vest based on both performance and time. They are subject to joint performance-based and time-based vesting requirements under the 2019 Plan and remain forfeitable until all specified conditions are met.

How did INBS’s reverse stock split affect the reported Form 4 amounts?

A 1-for-10 reverse stock split on December 15, 2025, reduced the number of shares held and adjusted outstanding equity awards. All share figures in this Form 4 are presented on a post-reverse-split basis, reflecting those adjustments.

Does this INBS Form 4 show any insider share sales by the CEO?

No sales are reported. The filing only shows two acquisition-type transactions coded as grants or awards of common stock, with no sell transactions, tax withholdings, or derivative exercises disclosed in the summarized data.